Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness.
Saved in:
| Title: | Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness. |
|---|---|
| Authors: | Silva, Berenice A. (AUTHOR), Heriz, Alejandra (AUTHOR), Ayerbe, Jeremías (AUTHOR), Lázaro, Luciana (AUTHOR), Casas, Magdalena (AUTHOR), López, Pablo (AUTHOR), Tkachuk, Verónica (AUTHOR), Balbuena, María Eugenia (AUTHOR), Nadur, Débora (AUTHOR), Liwacki, Susana (AUTHOR), Luetic, Geraldine (AUTHOR), Burgos, Marcos (AUTHOR), Casales, Federico (AUTHOR), Piedrabuena, Agustina (AUTHOR), Carnero Contentti, Edgar (AUTHOR), Zárate, Agustina (AUTHOR), Zanga, Gisela (AUTHOR), Steinberg, Judith (AUTHOR), Mainella, Carolina (AUTHOR), Tavolini, Darío (AUTHOR) |
| Source: | Neurological Sciences. Dec2024, Vol. 45 Issue 12, p5841-5848. 8p. |
| Subjects: | Learning curve, Drug efficacy, Demographic characteristics, Disease duration, Multiple sclerosis |
| Abstract: | Introduction: Cladribine was approved for Multiple Sclerosis (MS) in our country in 2018. A previous study by our group showed that its use among high efficacy therapies options has been increasing along the years. Objective: to analyze the cladribine use trend across time since its approval. Method: A retrospective cohort study was performed. People with MS (pwMS) treated with cladribine were included. Two periods were defined: P1 = 2018 – 2020 and P2 = 2021 – 2023. A comparative analysis was carry out between P1 and P2 to assess the trend of use, clinical/demographic characteristics, and effectiveness. Results: One hundred ninety- seven people with MS (pwMS) were included, mean EDSS: 2.2 ± 3.08, 72.6% female, mean age: 35.2 ± 9 years, mean disease duration: 6.6 ± 5.6 years, mean time lapse under cladribine: 26.1 ± 12.4 months. Regarding patient profile, we found significant differences between P1 and P2 in the MS evolution (p = 0.001) and EDSS (p = 0.018) prior to initiation of cladribine. In the individualized analysis by year, we found a decrease in relapse number in the year prior to starting cladribine (p = 0.02). A higher proportion of No Evidence of Disease Activity (NEDA) was found in patients treated at P2 compared to those treated at P1 (p < 0.001). Conclusion: An earlier use of cladribine achieved a significant increase in reaching NEDA. This learning curve in the use of cladribine allows a better identification of the candidate patient and influences the treatment effectiveness. [ABSTRACT FROM AUTHOR] |
| Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Introduction: Cladribine was approved for Multiple Sclerosis (MS) in our country in 2018. A previous study by our group showed that its use among high efficacy therapies options has been increasing along the years. Objective: to analyze the cladribine use trend across time since its approval. Method: A retrospective cohort study was performed. People with MS (pwMS) treated with cladribine were included. Two periods were defined: P1 = 2018 – 2020 and P2 = 2021 – 2023. A comparative analysis was carry out between P1 and P2 to assess the trend of use, clinical/demographic characteristics, and effectiveness. Results: One hundred ninety- seven people with MS (pwMS) were included, mean EDSS: 2.2 ± 3.08, 72.6% female, mean age: 35.2 ± 9 years, mean disease duration: 6.6 ± 5.6 years, mean time lapse under cladribine: 26.1 ± 12.4 months. Regarding patient profile, we found significant differences between P1 and P2 in the MS evolution (p = 0.001) and EDSS (p = 0.018) prior to initiation of cladribine. In the individualized analysis by year, we found a decrease in relapse number in the year prior to starting cladribine (p = 0.02). A higher proportion of No Evidence of Disease Activity (NEDA) was found in patients treated at P2 compared to those treated at P1 (p < 0.001). Conclusion: An earlier use of cladribine achieved a significant increase in reaching NEDA. This learning curve in the use of cladribine allows a better identification of the candidate patient and influences the treatment effectiveness. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 15901874 |
| DOI: | 10.1007/s10072-024-07763-7 |
